Zedoarondiol

Research use only, not for human use.

Zedoarondiol has anti-inflammatory activity, inhibits iNOS, COX-2, and pro-inflammatory cytokine expressions by suppressing the phosphorylations of IKK and MAPKs, and by subsequently inactivating the NF-kappaB pathway.

Zedoarondiol has anti-inflammatory activity, inhibits iNOS, COX-2, and pro-inflammatory cytokine expressions by suppressing the phosphorylations of IKK and MAPKs, and by subsequently inactivating the NF-kappaB pathway.

Zedoarondiol (5-20 μg/mL) attenuates HUVECs injury, up-regulated SOD activity, suppressed formation of MDA and ROS, and secretion and protein expression of IL-1β, TNF-α, and MCP-1 in injured HUVECs induced by oxidized low-density lipoprotein (ox-LDL). Zedoarondiol induces nuclear Nrf2 translocation from cytoplasm into nucleus and up-regulated expression of HO-1, NQO1, and Nrf2 in nucleus. Zedoarondiol suppresses PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation and DNA synthesis, and induces cell cycle arrest in G0/G1 phase. In addition, Zedoarondiol activates AMPK and ACC, inhibited the phosphorylation of mTOR and p70S6K, increases the expression of p53 and p21, and decreases the expression of CDK2 and cyclin E.

——

——

Others

Other Targets

——

——

——

98644-24-7

252.4

C15H24O3

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years